Aptevo Therapeutics Inc. (APVO) - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Aptevo Therapeutics Inc. on August 21, 2026. The filing details the voting outcomes for four specific proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Four proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Directors): Zsolt Harsanyi, Ph.D., and Barbara Lopez Kunz were elected to the Board of Directors for terms ending in 2029.
- Proposal 2 (Auditor Ratification): Shareholders approved the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for 2026.
- Proposal 3 (Say-on-Pay): The non-binding advisory vote on 2025 executive compensation was approved.
- Proposal 4 (Stock Incentive Plan): The Fourth Amended and Restated 2018 Stock Incentive Plan was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves strictly as a record of the shareholder vote.
Investor Verification Checklist
- Verify the definitive proxy statement filed on July 31, 2026, for detailed biographies of the newly elected directors.
- Review the approved Fourth Amended and Restated 2018 Stock Incentive Plan to understand potential dilution impacts.
- Confirm the engagement letter terms with the newly ratified auditor, Baker Tilly US, LLP.
- Check subsequent filings for the formal appointment of the new directors and any changes to the Board composition.